Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Sobrero · SciRah

Researcher profile · Semantic Scholar

A. Sobrero

Share profile

A. Sobrero — researcher profile on SciRah

h-index: 60
Works: 352
Citations: 22K

Most-cited papers

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
A. Grothey, A. Sobrero, A. Shields, T. Yoshino +19 more
2018New England Journal of Medicine851 citations Open access
Semantic Scholar
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
C. Eng, T. W. Kim, J. Bendell, G. Argilés +75 more
2019The Lancet Oncology480 citations Open access
Semantic Scholar
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
A. Dasari, S. Lonardi, R. García-Carbonero, E. Élez +33 more
2023The Lancet271 citations Open access
Semantic Scholar
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
T. André, J. Meyerhardt, T. Iveson, A. Sobrero +17 more
2020The Lancet Oncology225 citations Open access
Semantic Scholar
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
P. Philip, J. Lacy, F. Portales, A. Sobrero +17 more
2020The Lancet Gastroenterology and Hepatology205 citations
Semantic Scholar
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
E. Van Cutsem, E. Martinelli, S. Cascinu, A. Sobrero +19 more
2018The Oncologist140 citations Open access
Semantic Scholar
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
T. Iveson, A. Sobrero, T. Yoshino, I. Souglakos +18 more
2021Journal of Clinical Oncology84 citations Open access
Semantic Scholar
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
E. Fontana, J. Meyers, A. Sobrero, T. Iveson +20 more
2021Journal of Clinical Oncology81 citations Open access
Semantic Scholar
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
Q. Shi, A. Sobrero, A. Shields, T. Yoshino +16 more
201774 citations
Semantic Scholar
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A. Ruzzo, Francesco Graziano, F. Galli, F. Galli +26 more
2017British Journal of Cancer68 citations Open access
Semantic Scholar
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
A. Sobrero, S. Lonardi, G. Rosati, M. Di Bartolomeo +17 more
2018Journal of Clinical Oncology65 citations
Semantic Scholar
A new prognostic and predictive tool for shared decision making in stage III colon cancer.
A. Sobrero, A. Puccini, Q. Shi, A. Grothey +7 more
2020European Journal of Cancer61 citations
Semantic Scholar
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E. Van Cutsem, T. Yoshino, H. Lenz, S. Lonardi +15 more
2018Annals of Oncology60 citations Open access
Semantic Scholar
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
J. Tabernero, G. Argilés, A. Sobrero, C. Borg +5 more
2020ESMO Open59 citations Open access
Semantic Scholar
Prognostic and predictive molecular biomarkers in advanced colorectal cancer.
V. Martelli, A. Pastorino, A. Sobrero
2022Pharmacology and Therapeutics47 citations
Semantic Scholar
Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.
J. Bendell, F. Ciardiello, J. Tabernero, Niall C. Tebbutt +13 more
2018Annals of Oncology46 citations Open access
Semantic Scholar
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
F. Petrelli, R. Labianca, A. Zaniboni, S. Lonardi +19 more
2020JAMA Oncology45 citations Open access
Semantic Scholar
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
A. Dasari, A. Sobrero, James C. Yao, T. Yoshino +6 more
2021Future Oncology41 citations Open access
Semantic Scholar
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
T. Iveson, A. Sobrero, T. Yoshino, I. Sougklakos +15 more
2019Journal of Clinical Oncology41 citations
Semantic Scholar
Adjuvant Chemotherapy for Stage II Colon Cancer
S. E. Rebuzzi, G. Pesola, V. Martelli, A. Sobrero
2020Cancers40 citations Open access
Semantic Scholar
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
E. Van Cutsem, K. Muro, D. Cunningham, G. Bodoky +11 more
2020European Journal of Cancer40 citations Open access
Semantic Scholar
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
L. Renfro, R. Goldberg, A. Grothey, A. Sobrero +23 more
2017Journal of Clinical Oncology39 citations Open access
Semantic Scholar
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.
G. Bregni, S. Sciallero, A. Sobrero
2019JAMA Oncology36 citations
Semantic Scholar
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
Kaitlyn K. H. Goey, H. Sørbye, B. Glimelius, R. Adams +28 more
2018European Journal of Cancer35 citations Open access
Semantic Scholar
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
R. Cohen, D. Vernerey, C. Bellera, A. Meurisse +34 more
2020European Journal of Cancer33 citations Open access
Semantic Scholar
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
S. Lonardi, A. Sobrero, G. Rosati, M. Di Bartolomeo +18 more
2017Annals of Oncology32 citations Open access
Semantic Scholar
Changes in the Salivary Metabolic Profile of Generalized Periodontitis Patients after Non-surgical Periodontal Therapy: A Metabolomic Analysis Using Nuclear Magnetic Resonance Spectroscopy
F. Citterio, F. Romano, G. Meoni, G. Iaderosa +7 more
2020Journal of Clinical Medicine27 citations Open access
Semantic Scholar
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
C. Gallois, Q. Shi, J. Meyers, T. Iveson +20 more
2022Journal of Clinical Oncology26 citations Open access
Semantic Scholar
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
C. Gallois, Q. Shi, L. Pederson, T. André +21 more
2024Journal of Clinical Oncology23 citations Open access
Semantic Scholar
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
C. Cremolini, C. Montagut, P. Ronga, F. Venturini +3 more
2023Frontiers in Oncology22 citations Open access
Semantic Scholar
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
G. Argilés, D. Arnold, G. Prager, A. Sobrero +1 more
2019ESMO Open22 citations Open access
Semantic Scholar
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
R. Riechelmann, V. Srimuninnimit, R. Bordonaro, P. Kavan +18 more
2019Clinical colorectal cancer21 citations Open access
Semantic Scholar
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
A. Sobrero, H. Lenz, C. Eng, W. Scheithauer +5 more
2020The Oncologist20 citations Open access
Semantic Scholar
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
R. Cohen, M. Raeisi, B. Chibaudel, Q. Shi +29 more
2024European Journal of Cancer19 citations Open access
Semantic Scholar
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
H. Bleiberg, G. Decoster, A. de Gramont, P. Rougier +13 more
2017Annals of Oncology19 citations Open access
Semantic Scholar
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA Phase 3 Randomized Trial.
F. Petrelli, E. Rulli, R. Labianca, S. Lonardi +17 more
2020Annals of Oncology18 citations Open access
Semantic Scholar
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
S. Cascinu, R. Berardi, R. Bianco, D. Bilancia +21 more
2021European Journal of Cancer17 citations
Semantic Scholar
Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.
A. Ohtsu, T. Yoshino, A. Falcone, R. García-Carbonero +15 more
201717 citations
Semantic Scholar
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
A. Ruzzo, F. Graziano, F. Galli, F. Galli +25 more
2019Scientific Reports15 citations Open access
Semantic Scholar
ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
A. Puccini, V. Martelli, A. Pastorino, S. Sciallero +1 more
2023Current Treatment Options in Oncology13 citations
Semantic Scholar
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
A. Avallone, F. Giuliani, A. De Stefano, G. Santabarbara +22 more
2024Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
A. Sobrero, A. Dasari, S. Lonardi, R. García-Carbonero +16 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
A. Avallone, F. Giuliani, G. Nasti, V. Montesarchio +16 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?
A. Sobrero, A. Pastorino, John R. Zalcberg
2022Journal of Clinical Oncology10 citations
Semantic Scholar
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database
J. Bachet, A. de Gramont, M. Raeisi, Manel Rakez +17 more
2025Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial
S. Barni, G. Rosati, S. Lonardi, N. Pella +27 more
2020Therapeutic Advances in Medical Oncology8 citations Open access
Semantic Scholar
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
J. Tabernero, A. Sobrero, C. Borg, A. Ohtsu +4 more
2019Journal of Clinical Oncology8 citations
Semantic Scholar
FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.
A. Sobrero, S. Lonardi, G. Rosati, M. Di Bartolomeo +16 more
20178 citations
Semantic Scholar
Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial
D. Cunningham, R. Salazar, A. Sobrero, M. Ducreux +9 more
2019Annals of Oncology6 citations Open access
Semantic Scholar
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.
A. Shields, F. Ou, J. Paul, A. Sobrero +16 more
20186 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Labianca×20
Invite
R. Labianca — researcher profile on SciRah
S. Lonardi×16
Invite
S. Lonardi — researcher profile on SciRah
T. Yoshino×15
Invite
T. Yoshino — researcher profile on SciRah
E. Van Cutsem×14
Invite
E. Van Cutsem — researcher profile on SciRah

×11

Invite

Q. Shi — researcher profile on SciRah

Invite

T. Iveson — researcher profile on SciRah

Invite

A. Grothey — researcher profile on SciRah

Invite

T. André — researcher profile on SciRah

I. Boukovinas×9

Invite

I. Boukovinas — researcher profile on SciRah

Invite

E. Maiello — researcher profile on SciRah

Invite

A. Zaniboni — researcher profile on SciRah

Invite

G. Rosati — researcher profile on SciRah